Client news
Entera closes $10 million BVF-led direct investment, with up to $24.5 million potential
A significant milestone for Entera Bio Ltd. (NASDAQ: ENTX).
Entera successfully closed a $10 million direct investment led by BVF Partners, a leading institutional healthcare fund, with total potential proceeds of up to $24.5 million.
This is more than capital. It is a vote of confidence. The financing is expected to support initiation of Entera’s Phase 3 registration study for EB613, a critical step toward potential commercialization and a broader shift in how peptide therapies are delivered.